Helius Medical Technologies, Inc. Share Price

Equities

HSDT

US42328V8019

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:30:00 26/04/2024 BST 5-day change 1st Jan Change
4.5 USD +1.35% Intraday chart for Helius Medical Technologies, Inc. -12.54% -44.02%
Sales 2024 * 977K 78.23M Sales 2025 * 5.72M 458M Capitalization 3.99M 320M
Net income 2024 * -11M -881M Net income 2025 * -9M -721M EV / Sales 2024 * 4.09 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.7 x
P/E ratio 2024 *
-0.43 x
P/E ratio 2025 *
-1.02 x
Employees 22
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.15%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.35%
1 week-12.54%
Current month-22.81%
1 month-19.64%
3 months-35.71%
6 months-36.35%
Current year-44.02%
More quotes
1 week
4.42
Extreme 4.42
5.10
1 month
4.42
Extreme 4.42
7.19
Current year
4.29
Extreme 4.29
9.50
1 year
4.29
Extreme 4.29
14.44
3 years
4.29
Extreme 4.29
871.00
5 years
4.29
Extreme 4.29
5 792.51
10 years
4.29
Extreme 4.29
36 225.04
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 03/08/17
Director of Finance/CFO 63 08/06/20
Chief Tech/Sci/R&D Officer 57 07/07/21
Members of the board TitleAgeSince
Director/Board Member 85 17/11/14
Chief Executive Officer 58 03/08/17
Chairman 53 28/12/15
More insiders
Date Price Change Volume
26/04/24 4.5 +1.35% 5,124
25/04/24 4.44 -7.79% 13,586
24/04/24 4.815 -3.31% 17,231
23/04/24 4.98 -1.87% 4,077
22/04/24 5.075 -1.36% 8,376

Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm

More quotes
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.5 USD
Average target price
15.47 USD
Spread / Average Target
+243.70%
Consensus